Complete Guide to Fruquintinib Pharmacokinetics
Overview
Fruquintinib is a VEGFR Tyrosine Kinase Inhibitor used in the Metastatic Colorectal Cancer therapeutic area. It is indicated for Metastatic Colorectal Cancer. Interactive population pharmacokinetic simulator for fruquintinib (FRUZAQLA), a selective VEGFR-1/2/3 tyrosine kinase inhibitor for metastatic colorectal cancer. One-compartment model based on Zhou et al. 2025 (J Clin Pharmacol).
Key Pharmacokinetic Parameters
This PopPK model for Fruquintinib characterizes the time-course of drug concentrations following Oral administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Fruquintinib is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Metastatic Colorectal Cancer therapeutic area, for the treatment of Metastatic Colorectal Cancer, understanding the pharmacokinetics of Fruquintinib is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Fruquintinib pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Fruquintinib PK Simulator
Explore Fruquintinib pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Fruquintinib?
The elimination half-life of Fruquintinib depends on patient-specific factors. Use our interactive Fruquintinib PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Fruquintinib administered?
Fruquintinib is administered via the Oral route. It is indicated for Metastatic Colorectal Cancer. As a VEGFR Tyrosine Kinase Inhibitor, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Fruquintinib?
Key pharmacokinetic parameters for Fruquintinib include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a PopPK model to characterize the pharmacokinetics of Fruquintinib.
Can I simulate Fruquintinib dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Fruquintinib PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.